PDCD1 and neoplasm: Likewise, we administered a sufficient pre-dose of non-radioactive pembrolizumab to block off-target hPD-1 binding in multiple organs, including in the tumor, to distinguish the specific binding of the 64Cu-pembrolizumab tracer.